City of Hope Medical Center: Leukemia, Myeloid, Acute trials

The registry lists 51 Leukemia, Myeloid, Acute studies with City of Hope Medical Center as lead sponsor. 15 are open to participants now and 9 have results posted.

Early Phase 1 1Phase 1 32Phase 2 17No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Individualized AML TreatmentRecruitingNCT07613385
• BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 MutationNot yet recruitingNCT07583303Phase 1
• Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeRecruitingNCT07582172Phase 2
• MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT07025564Phase 1
• A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell TransplantRecruitingNCT07020533Phase 1
• Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantRecruitingNCT06996119Phase 1
• Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningRecruitingNCT06815003Phase 2
• A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06763341Phase 1
• Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell TransplantRecruitingNCT06575296Phase 1
• Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantRecruitingNCT06543381Phase 1
• Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell TransplantRecruitingNCT06498973Phase 1
• 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingNCT06287944Phase 1
• Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeRecruitingNCT06128070Phase 2
• CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
• CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid LeukemiaRecruitingNCT05672147Phase 1
• Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04060277Phase 2Results posted
• 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02509546Phase 1/2Results posted
• Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid LeukemiaTerminatedNCT01876953Phase 1/2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological MalignanciesActive, not recruitingNCT00544466Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid CancerTerminatedNCT00540995Phase 1/2Results posted
• Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep RCompletedNCT00534469Phase 2Results posted
• Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic CancerCompletedNCT00534430Phase 2Results posted
• Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched DonorWithdrawnNCT06572631Phase 1
• Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid LeukemiaSuspendedNCT06454409Phase 1
• Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic SyndromeSuspendedNCT06195891Phase 1
• Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT05441514Phase 1
• A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer SurvivorsActive, not recruitingNCT05428176Not applicable
• Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
• 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid LeukemiaSuspendedNCT05263284Phase 1
• Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxActive, not recruitingNCT05222984Phase 1
• 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05139004Phase 1
• Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnNCT04655391Phase 1
• Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST StudyActive, not recruitingNCT04537871
• Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaActive, not recruitingNCT04262843Phase 2
• Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractorySuspendedNCT03969446Phase 1
• Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationSuspendedNCT03728335Phase 2
• Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic SyndromeSuspendedNCT03494569Phase 1
• Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03467386Phase 1
• Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and ChemotherapyActive, not recruitingNCT03422731Early Phase 1
• High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic LymphomaActive, not recruitingNCT03178617Not applicable
• Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaCompletedNCT03009240Phase 1
• Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
• Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute LeukemiaCompletedNCT02446964Phase 1
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmActive, not recruitingNCT02159495Phase 1
• Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AMLActive, not recruitingNCT02094794Phase 2
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
• 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01041443Phase 1
• Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00641030Phase 1